AVI BioPharma signs agreement with US Defense Threat Reduction Agency for H1N1 Swine Flu therapeutics
Do you know when to trade AVII ?
AVII | Quote | Chart | News | PowerRating -- AVI BioPharma, Inc., a developer of RNA-based drugs, has signed an agreement with the US Defense Threat Reduction Agency (DTRA) for the development of one or more nucleotide-based candidate drugs targeting the epidemic of H1N1 swine flu. DTRA is a division of US Department of Defense. Both the partners are based in the US.
Under the terms of the agreement, AVI BioPharma would analyze the H1N1 sequence, determine appropriate targets, and identify lead and back-up candidate drugs. AVI BioPharma would also manufacture development grade material in sufficient quantities for planned animal tests and perform animal studies for lead and back-up candidate drugs.
As part of the agreement, DTRA would pay up to $5.1 million to AVI BioPharma for the work. The work would involve the application of the AVI BioPharma's propriety PMOplus antisense chemistry.
Deal Type Partnership
Sub-Category Research and discovery,Development
Deal Status Announced: 2009-06-22
Deal Participants
Partner 1 (Company) U.S. Department of Defense
Partner 2 (Company) AVI BioPharma, Inc.
Partner 3 (Company) Defense Threat Reduction Agency
For full details on Avi Biopharma Inc (AVII) AVII. Avi Biopharma Inc (AVII) has Short Term PowerRatings at TradingMarkets. Details on Avi Biopharma Inc (AVII) Short Term PowerRatings is available at This Link.
- Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity - 03/18/10
- AVI Biopharma Inc (AVII) Corporate Event Announcement Notice - 03/17/10
- AVI Biopharma Inc (AVII) Corporate Event Announcement Notice - 03/16/10
- AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results - 03/16/10
- Conference Calls Today: 8:30 A.M. EST - 03/16/10
- More News >>


